<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164960">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02102997</url>
  </required_header>
  <id_info>
    <org_study_id>DTS.DE Register V 1.2</org_study_id>
    <nct_id>NCT02102997</nct_id>
  </id_info>
  <brief_title>Deutsches Dual Therapy Stent Register</brief_title>
  <acronym>DTS Register</acronym>
  <official_title>Deutsches Dual Therapy Stent Register</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OrbusNeich</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OrbusNeich</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The DTS.DE registry is an initiative for the collection of high quality process and
      historical data of implantations with the COMBO Dual Therapy Stent in Germany. DTS.DE was
      designed as a national, non- randomized, prospective, multicenter registry without a
      comparison group.

      The responsible Steering Committee is of the opinion that the Combo stent qualifies for
      further documentation of treatment results in the form of a German registry, based the CE
      certification of the COMBO Dual Therapy stent in 2013 and its clinical and scientific
      investigation in the context of the REMEDEE study program, as well as company independent
      externally initiated studies with the COMBO Dual Therapy Stent.

      It is expected that by mid- 2015, at least 1,000 patients will be enrolled and documented in
      the DTS.DE registry with the COMBO Dual Therapy Stent. A clinical follow-up is performed
      after 6 weeks and 12 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is the objective of the DTS.DE registry to capture the documentation of all patients  who
      have been treated with a Combo Dual Therapy Stent in Germany, and who have been properly
      informed and consented with regards to their participation in the registry. All of these
      patients will be registered in the electronic data capturing system (eCRF) of the DTS.DE
      registry and will be followed and documented for a period of 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Ecologic or Community, Time Perspective: Prospective</study_design>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Target Vessel Failure (TVF)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>TVF is defined as the hierarchical composite of target vessel related Major Adverse Cardiac Events (MACE). MACE is defined as the composite of death, myocardial infarction and  target lesion revascularization (TLR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural success</measure>
    <time_frame>Day of procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Successful implantation of the stent and a residual stenosis of less than 20%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>6 weeks and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>MACE is defined as the composite of of death, myocardial infarction and target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent induced serious adverse events (SAE)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Classified per ARC definitions as definite, probable or possible stent thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombolysis in Myocardial Infarction (TIMI) bleeding</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Bleeding as defined by the TIMI criteria: major, minor or minimal</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Coronary Artery Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients in Germany who have undergone PCI with the COMBO Dual Therapy Stent.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients has at least one coronary lesion, suitable for PCI treatment with the Combo
             stent in accordance with European Society of Cardiology Guidelines and local
             Guidelines of the Deutsche Gesellschaft für Kardiologie for drug eluting stents

        Exclusion Criteria:

          -  Patient has previously received murine therapeutic antibodies and exhibited
             sensitization through the production of Human Anti- Murine Antibodies (HAMA)

          -  Patient in whom anti-platelet and/or anticoagulant therapy is contraindicated

          -  Patient in whom a complete inflation of the angioplasty balloon or correct stent
             placement is thought to be inhibited
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jochen Wöhrle, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Universitätsklinikum Ulm, Klinik für Innere Medizin II Albert-Einstein-Allee 23, 89081 Ulm, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Haude, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Kardiologie Lukaskrankenhaus Neuss Preußenstraße 84 D-41464 Neuss, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernward Lauer, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Klinik für Kardiologie, Zentralklinik Bad Berka GmbH, Robert-Koch-Allee 9 99437 Bad Berka, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Volker Schächinger, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Kardiologie, Angiologie, Pneumologie, Intensivmedizin Klinikum Fulda gAG Pacelliallee 4 - 36043 Fulda, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erdmann Zippel</last_name>
    <phone>+49 6202 127360</phone>
    <email>erdmann.zippel@aptivsolutions.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kardiologie Lukaskrankenhaus Neuss</name>
      <address>
        <city>Neuss</city>
        <zip>D-41464</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Haude, MD, PhD</last_name>
      <phone>+4921318882000</phone>
      <email>mhaude@lukasneuss.de</email>
    </contact>
    <investigator>
      <last_name>Michael Haude, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 31, 2014</lastchanged_date>
  <firstreceived_date>March 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DTS</keyword>
  <keyword>Stents</keyword>
  <keyword>Stent</keyword>
  <keyword>DES</keyword>
  <keyword>Drug eluting</keyword>
  <keyword>Drug Eluting Stent (DES)</keyword>
  <keyword>Drug eluting stents</keyword>
  <keyword>Endothelial Progenitor Cell (EPC)</keyword>
  <keyword>Endothelial progenitor cell capturing</keyword>
  <keyword>Sirolimus</keyword>
  <keyword>Sirolimus eluting</keyword>
  <keyword>Percutaneous Coronary Intervention (PCI)</keyword>
  <keyword>PCI</keyword>
  <keyword>Registry</keyword>
  <keyword>Registries</keyword>
  <keyword>Multi center</keyword>
  <keyword>Multi centre</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
